William Harvey Research Institute, Queen Mary University of London, London, UK.
Barts Heart Centre, St. Bartholomew's Hospital, Barts Health NHS Trust, London, UK.
Hum Vaccin Immunother. 2023 Dec 31;19(1):2188823. doi: 10.1080/21645515.2023.2188823. Epub 2023 Mar 28.
Given the potential for nosocomial outbreaks, we must understand factors associated with negative vaccine attitudes amongst healthcare professionals (HCPs) before the rollout of a newly developed vaccine in a pandemic setting. The aim of this prospective cohort study was to study the impact of preexisting and prevailing mental health on United Kingdom HCPs' attitudes towards a newly developed COVID-19 vaccine. Two online surveys were distributed: first during vaccine development (July-September, 2020) and second during nationwide vaccine rollout (December 2020-March 2021). Mental health (PHQ-9 for depression; GAD-7 for anxiety) was assessed in both surveys. Negative attitude regarding vaccine safety and vaccine effectiveness was assessed at vaccine rollout. A series of logistic regression models were developed relating mental health (preexisting during vaccine development, ongoing and new-onset during rollout, and changes in symptom severity) to negative vaccine attitudes. In 634 HCPs, the presence of depression and/or anxiety during vaccine development was associated with elevated negative attitude towards vaccine safety (adj. OR 1.74 [95% CI 1.10-2.75], = .02), but not vaccine effectiveness (1.13 [0.77-1.66], = .53) at rollout. This was independent of other characteristics: age, ethnicity, professional role, and history of contracting COVID-19. Ongoing depression and/or anxiety (1.72 [1.10-2.69], = .02) was associated with elevated negative attitude regarding vaccine effectiveness, but not vaccine safety. Worsened combined symptom scores over time were associated with elevated negative vaccine effectiveness attitudes (1.03 [1.00-1.05], < .05), but not vaccine safety. Overall, adverse mental health can impact on HCPs' attitudes towards a newly developed vaccine. Further work is required to understand how this translates to vaccine uptake.
鉴于医院感染爆发的可能性，我们必须在大流行背景下新开发的疫苗推出之前，了解与医疗保健专业人员（HCP）负面疫苗态度相关的因素。本前瞻性队列研究的目的是研究预先存在和普遍存在的心理健康对英国 HCP 对新开发的 COVID-19 疫苗的态度的影响。进行了两次在线调查：第一次是在疫苗开发期间（2020 年 7 月至 9 月），第二次是在全国疫苗推出期间（2020 年 12 月至 2021 年 3 月）。两次调查均评估了心理健康状况（抑郁的 PHQ-9；焦虑的 GAD-7）。在疫苗推出时评估对疫苗安全性和疫苗有效性的负面态度。建立了一系列逻辑回归模型，将心理健康（疫苗开发期间存在、推出期间持续存在和新出现、症状严重程度变化）与负面疫苗态度相关联。在 634 名 HCP 中，疫苗开发期间存在抑郁和/或焦虑与对疫苗安全性的负面态度升高相关（调整后的 OR 1.74 [95% CI 1.10-2.75]， = .02），但与疫苗有效性无关（1.13 [0.77-1.66]， = .53）。这独立于其他特征：年龄、种族、专业角色和感染 COVID-19 的历史。持续存在的抑郁和/或焦虑（1.72 [1.10-2.69]， = .02）与对疫苗有效性的负面态度升高相关，但与疫苗安全性无关。随着时间的推移，综合症状评分恶化与对疫苗有效性的负面态度升高相关（1.03 [1.00-1.05]， < .05），但与疫苗安全性无关。总的来说，不良心理健康状况会影响 HCP 对新开发疫苗的态度。需要进一步研究如何将其转化为疫苗接种率。
